Developer docs
API playgroundTry for free, no card

Search company profiles

Emenda Therapeutics

Full company profile

uuid000vy21

Namestring
Emenda Therapeutics
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Emenda Therapeutics is a privately held, early-stage biotechnology company headquartered in Bristol, United Kingdom, that is developing small-molecule inhibitors of splicing factor kinases for the treatment of chronic pain. The company's therapeutic hypothesis targets a specific kinase class involved in RNA splicing regulation as a non-opioid mechanism for pain modulation, addressing a large unmet-need indication with significant commercial potential. Emenda operates with a small team of 1-10 employees and is led by co-founder Stephen Harper, with Andy Chapman serving as non-executive director; no broader management team, scientific advisory board, or research staff is disclosed in the source materials.

The company has no disclosed products, pipeline assets, patents, trademarks, or proprietary chemistry filings in the available data. The corporate website (emendatherapeutics.com) returns only a verification/loading page with no substantive content, indicating a minimal public-facing presence. No pricing, distribution, marketing channels, certifications, or regulatory milestones are documented. The source data captures no funding rounds, investments, subsidiaries, parent entities, mergers, acquisitions, or restructuring events.

From a business model standpoint, Emenda is structured as a for-profit private company with no disclosed revenue, no commercial customers, and no partnerships or alliances on record. The operating model is consistent with a preclinical or early discovery-stage biotech: capital is the primary input, and any future monetization would likely flow through out-licensing, co-development partnerships, or acquisition rather than direct product sales. No third-party collaborators, academic institutions, contract research organizations, or pharmaceutical partners are named, leaving the company's translational pathway and financing strategy undisclosed in the input data.

Short descriptiontext

Emenda Therapeutics is a Bristol, UK-based private biotech developing small-molecule inhibitors of splicing factor kinases for the treatment of chronic pain. The company operates with 1-10 employees and shows no disclosed products, partnerships, or commercial activity.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSouthport, Australia
HQ citystring
Southport
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Keyword5 values
small molecule kinase inhibitors, chronic pain therapeutics, splicing factor kinase drug discovery, preclinical biotechnology research, RNA splicing therapeutics
Industry3 codes
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
Product category
Pain Therapeutics / Pharmaceutical R&D
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Emenda Therapeutics is developing inhibitors of splicing factor kinases for the treatment of chronic pain. The company is engaged in early-stage drug discovery targeting RNA splicing-related kinase biology to create therapeutics intended for patients with chronic pain conditions. The company is research-stage with no marketed products evidenced.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Splicing factor kinase inhibitor program (chronic pain)
CategoryPain Therapeutics / Pharmaceutical R&D
Description

Early-stage research program developing small-molecule inhibitors of splicing factor kinases intended for the treatment of chronic pain. The asset is at a pre-clinical or early-clinical stage and is not yet a marketed therapy; it is the company's primary therapeutic pipeline candidate.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Skyhawk develops RNA-binding small molecules that modulate RNA splicing, directly targeting a similar druggable mechanism (splicing biology) for therapeutic intervention making it a technology peer.

2Convergence Pharmaceuticals
TypeDirect peer
Description

Former UK-based pain-focused biotech developing novel therapeutics for chronic pain conditions; represents an archetype of UK pain-focused biotech that Emenda could resemble in trajectory.

TypeEmerging player
Description

Accent Therapeutics targets RNA-modifying proteins for cancer therapy; a technology peer in the RNA-modulating therapeutics space with comparable scientific approach.

4H3 Biomedicine
TypeEmerging player
Description

Focused on RNA splicing and cancer therapeutics, H3 Biomedicine targets splicing biology with small molecules; comparable to Emenda's splicing-focused approach but in oncology.

TypeDirect peer
Description

Cara Therapeutics develops novel therapeutics for pain with a differentiated mechanism; a direct peer in the chronic pain therapeutics space.

TypeEmerging player
Description

ProQR develops RNA-based therapeutics, including approaches that target RNA splicing; comparable as a technology peer in the RNA-modulating therapeutics space.

TypeBroad incumbent
Description

Lexicon has developed pain therapeutics and operates a broader pipeline; a broader incumbent with comparable pain therapeutic activity.

TypeBroad incumbent
Description

ACADIA has significant commercial pain-related programs and CNS franchise; a broader incumbent in the pain therapeutics space with established commercial and development capabilities.

TypeRegional player
Description

UK-based cannabinoid therapeutics company (now part of Jazz Pharmaceuticals) that pioneered plant-derived therapeutics for pain and other indications; a UK regional peer with successful exit trajectory.

TypeDirect peer
Description

Trevena is a clinical-stage pain therapeutics company developing novel mechanism pain treatments; directly comparable as a fellow pain-focused biotech.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Emenda Therapeutics

Pain Therapeutics / Pharmaceutical R&Demendatherapeutics.com

Emenda Therapeutics is a Bristol, UK-based private biotech developing small-molecule inhibitors of splicing factor kinases for the treatment of chronic pain. The company operates with 1-10 employees and shows no disclosed products, partnerships, or commercial activity.

What Emenda Therapeutics does

Emenda Therapeutics is a privately held, early-stage biotechnology company headquartered in Bristol, United Kingdom, that is developing small-molecule inhibitors of splicing factor kinases for the treatment of chronic pain. The company's therapeutic hypothesis targets a specific kinase class involved in RNA splicing regulation as a non-opioid mechanism for pain modulation, addressing a large unmet-need indication with significant commercial potential. Emenda operates with a small team of 1-10 employees and is led by co-founder Stephen Harper, with Andy Chapman serving as non-executive director; no broader management team, scientific advisory board, or research staff is disclosed in the source materials.

The company has no disclosed products, pipeline assets, patents, trademarks, or proprietary chemistry filings in the available data. The corporate website (emendatherapeutics.com) returns only a verification/loading page with no substantive content, indicating a minimal public-facing presence. No pricing, distribution, marketing channels, certifications, or regulatory milestones are documented. The source data captures no funding rounds, investments, subsidiaries, parent entities, mergers, acquisitions, or restructuring events.

From a business model standpoint, Emenda is structured as a for-profit private company with no disclosed revenue, no commercial customers, and no partnerships or alliances on record. The operating model is consistent with a preclinical or early discovery-stage biotech: capital is the primary input, and any future monetization would likely flow through out-licensing, co-development partnerships, or acquisition rather than direct product sales. No third-party collaborators, academic institutions, contract research organizations, or pharmaceutical partners are named, leaving the company's translational pathway and financing strategy undisclosed in the input data.

Emenda Therapeutics firmographics

Firmographics
Name
Emenda Therapeutics
Website
https://emendatherapeutics.com
Company type
Private
Headcount range
1–10 employees
Short description
Emenda Therapeutics is a Bristol, UK-based private biotech developing small-molecule inhibitors of splicing factor kinases for the treatment of chronic pain. The company operates with 1-10 employees and shows no disclosed products, partnerships, or commercial activity.
Ownership category
akta.pro rank

Emenda Therapeutics industry classification

Industry
Product category
Pain Therapeutics / Pharmaceutical R&D
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
akta.pro industry
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Small molecule kinase inhibitors
  • Chronic pain therapeutics
  • Splicing factor kinase drug discovery
  • Preclinical biotechnology research
  • RNA splicing therapeutics

Where Emenda Therapeutics is headquartered

Location

Headquarters

HQ city
Southport
HQ country
Australia
HQ region
Oceania

Markets served

Emenda Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Emenda Therapeutics product offering

Product offering

Core offering

Emenda Therapeutics is developing inhibitors of splicing factor kinases for the treatment of chronic pain. The company is engaged in early-stage drug discovery targeting RNA splicing-related kinase biology to create therapeutics intended for patients with chronic pain conditions. The company is research-stage with no marketed products evidenced.

Differentiator

Problem solved

Functional benefit

Products and services

  • Splicing factor kinase inhibitor program (chronic pain) Early-stage research program developing small-molecule inhibitors of splicing factor kinases intended for the treatment of chronic pain. The asset is at a pre-clinical or early-clinical stage and is not yet a marketed therapy; it is the company's primary therapeutic pipeline candidate.

Companies that use Emenda Therapeutics

Customer profile

Ideal customer profiles1 record

Emenda Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Emenda Therapeutics partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights3 records

Emenda Therapeutics competitors and assessment

Company assessment

Emerging players

  • Skyhawk Therapeutics: Skyhawk develops RNA-binding small molecules that modulate RNA splicing, directly targeting a similar druggable mechanism (splicing biology) for therapeutic intervention making it a technology peer.
  • Accent Therapeutics: Accent Therapeutics targets RNA-modifying proteins for cancer therapy; a technology peer in the RNA-modulating therapeutics space with comparable scientific approach.
  • H3 Biomedicine: Focused on RNA splicing and cancer therapeutics, H3 Biomedicine targets splicing biology with small molecules; comparable to Emenda's splicing-focused approach but in oncology.
  • ProQR Therapeutics: ProQR develops RNA-based therapeutics, including approaches that target RNA splicing; comparable as a technology peer in the RNA-modulating therapeutics space.

Direct peers

  • Convergence Pharmaceuticals: Former UK-based pain-focused biotech developing novel therapeutics for chronic pain conditions; represents an archetype of UK pain-focused biotech that Emenda could resemble in trajectory.
  • Cara Therapeutics: Cara Therapeutics develops novel therapeutics for pain with a differentiated mechanism; a direct peer in the chronic pain therapeutics space.
  • Trevena Inc. Trevena is a clinical-stage pain therapeutics company developing novel mechanism pain treatments; directly comparable as a fellow pain-focused biotech.

Broad incumbents

  • Lexicon Pharmaceuticals: Lexicon has developed pain therapeutics and operates a broader pipeline; a broader incumbent with comparable pain therapeutic activity.
  • ACADIA Pharmaceuticals: ACADIA has significant commercial pain-related programs and CNS franchise; a broader incumbent in the pain therapeutics space with established commercial and development capabilities.

Regional players

  • GW Pharmaceuticals: UK-based cannabinoid therapeutics company (now part of Jazz Pharmaceuticals) that pioneered plant-derived therapeutics for pain and other indications; a UK regional peer with successful exit trajectory.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Emenda Therapeutics social profiles

Digital presence

Emenda Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Emenda Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

Emenda Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Emenda Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emenda Therapeutics

What does Emenda Therapeutics do?

Emenda Therapeutics is developing inhibitors of splicing factor kinases for the treatment of chronic pain. The company is engaged in early-stage drug discovery targeting RNA splicing-related kinase biology to create therapeutics intended for patients with chronic pain conditions. The company is research-stage with no marketed products evidenced.

When was Emenda Therapeutics founded?

Emenda Therapeutics was founded in -1. It employs 1 to 10 people.

Where is Emenda Therapeutics based?

Emenda Therapeutics is headquartered in Southport, Australia, in the Oceania region.

Who are Emenda Therapeutics's main competitors?

Emerging players on record are Skyhawk Therapeutics, Accent Therapeutics, H3 Biomedicine and ProQR Therapeutics. Direct peers are Convergence Pharmaceuticals, Cara Therapeutics and Trevena Inc.. Broad incumbents are Lexicon Pharmaceuticals and ACADIA Pharmaceuticals. GW Pharmaceuticals is listed as a regional player.

Does Emenda Therapeutics have an API?

No public API is recorded for Emenda Therapeutics.

What industry is Emenda Therapeutics in?

Emenda Therapeutics's product category is Pain Therapeutics / Pharmaceutical R&D. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales